Breaking News: Bristol Myers Squibb (BMS) is forging ahead with its ADEPT-2 Phase 3 study, a crucial step in exploring potential treatments for psychosis associated with Alzheimer's disease. This is a significant development, offering a glimmer of hope for those grappling with this challenging condition.
The decision to continue the study comes after a meticulous review of the data collected from various study sites. BMS, committed to the highest standards in clinical research, identified some irregularities in how the clinical trials were conducted at a handful of these sites. As a result, before finalizing the data, they made the proactive decision to exclude the data from those specific sites from the primary analysis. This ensures the integrity of the research.
But here's where it gets interesting: the U.S. Food and Drug Administration (FDA) was consulted, and an independent Data Monitoring Committee (DMC) was brought in to analyze the interim data for both efficacy and safety. Following this in-depth analysis, the DMC recommended that the study continue by enrolling more patients to meet the original target population. Based on this recommendation, BMS will proceed with enrolling additional patients, following the DMC's guidance. BMS remains completely unaware of the study data.
"We agree with the decision to continue the Phase 3 study," stated Dr. Laura Gault, Senior Vice President and Head of Development, Neuroscience Drug Development at Bristol Myers Squibb. "Our dedication to excluding data from sites with irregularities reflects our commitment to maintaining the integrity of our studies. Psychosis related to Alzheimer's Disease is a critical area with a significant unmet medical need, and upholding rigorous standards is crucial as we work to find innovative treatment options for patients and families affected by this devastating condition."
Currently, Cobenfy is approved for treating schizophrenia in adults. It holds the potential to become the first treatment in a new class of pharmacologic therapies targeting agitation and psychosis through muscarinic receptor agonism. Additional results from the ADEPT program, including ADEPT-2, ADEPT-1, and ADEPT-4, are anticipated by the end of 2026.
BMS is taking a comprehensive approach to developing novel treatments for Alzheimer’s Disease. They are simultaneously pursuing investigational therapies that aim to slow down disease progression and ease symptoms, striving to give patients, families, and caregivers some of what this disease has taken away.
About ADEPT-2: The ADEPT-2 study (clinicaltrials.gov, NCT06126224) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. It is designed to evaluate the safety and effectiveness of Cobenfy in individuals experiencing psychosis linked to Alzheimer’s disease dementia. The primary goal is to assess changes in the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score, with the Clinical Global Impression-Severity (CGI-S) as a key secondary endpoint. The study also includes assessments of the safety and tolerability of Cobenfy compared to a placebo.
About Bristol Myers Squibb: Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines to help patients overcome serious diseases.
Now, here's a thought-provoking question: Do you believe that excluding data from certain sites, despite the potential delays, is the right approach to ensure the integrity of clinical trials? Share your thoughts in the comments below – we'd love to hear your perspective!
